🔴 Merck is trading 3.06% down today amid Vaxcyte’s positive Phase 3 VAX-31 results

Merck is trading 3.06% lower at $139.88 amid Vaxcyte’s positive Phase 3 results for VAX-31; coverage does not explicitly attribute Merck’s decline to the announcement.

• VAX-31 met its primary endpoints and produced immune responses comparable to Merck’s Capvaxive against shared strains.
• The results may intensify vaccine-market competition. Major indexes were mixed, with no broad same-direction decline clearly explaining Merck’s move.